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Abstract 
Background: Left ventricular (LV) dysfunction is closely associated with LV hypertrophy or diabetes, as well as insuf-
ficient autophagic flux. Acute or chronic hyperglycemia is a prognostic factor for patients with myocardial infarc-
tion. However, the effect of acute hyperglycemia on LV dysfunction of the hypertrophic heart and the mechanisms 
involved are still unclear. This study aimed to confirm our hypothesis that either acute or chronic hyperglycemia 
suppresses LV diastolic function and autophagic flux.
Methods: The transverse aortic constriction (TAC) model and streptozocin-induced type 1 diabetic mellitus mice 
were used. LV function was evaluated with a Millar catheter. Autophagic levels and autophagic flux in the whole heart 
and cultured neonatal rat cardiomyocytes in response to hyperglycemia were examined by using western blotting 
of LC3B-II and P62. We also examined the effect of an autophagic inhibitor on LC3B-II and P62 protein expression and 
LC3 puncta.
Results: In mice with TAC, we detected diastolic dysfunction as early as 30 min after TAC. This dysfunction was indi-
cated by a greater LV end-diastolic pressure and the exponential time constant of LV relaxation, as well as a smaller 
maximum descending rate of LV pressure in comparison with sham group. Similar results were also obtained in mice 
with TAC for 2 weeks, in addition to increased insulin resistance. Acute hyperglycemic stress suppressed diastolic func-
tion in mice with myocardial hypertrophy, as evaluated by invasive LV hemodynamic monitoring. Mice with chronic 
hyperglycemia induced by streptozocin showed myocardial fibrosis and diastolic dysfunction. In high glucose-treated 
cardiomyocytes and streptozocin-treated mice, peroxisome proliferator-activated receptor-γ coactivator 1α was 
downregulated, while P62 was upregulated. Autophagic flux was also significantly inhibited in response to high glu-
cose exposure in angiotensin-II treated cardiomyocytes.
Conclusions: Acute hyperglycemia suppresses diastolic function, damages mitochondrial energy signaling, and 
inhibits autophagic flux in prohypertrophic factor-stimulated cardiomyocytes.
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Background
Left ventricular (LV) diastolic dysfunction is present in 
various cardiovascular diseases such as hypertension [1], 
myocardial hypertrophy [2–4], coronary heart disease [5], 
and diabetes mellitus (DM) [6, 7]. Worsening of diastolic 
dysfunction is a predictor of mortality in cardiovascular 
diseases and some severe non-cardiovascular diseases, 
including septic shock and acute pancreatitis [8–10]. 
The detrimental role of chronic hyperglycemia and DM 
on diastolic function has been well recognized [11]. The 
prognostic value of acute hyperglycemia in patients with 
acute myocardial infarction has also attracted attention 
of clinical investigators [12]. However, whether acute 
hyperglycemia is a factor that worsens diastolic dysfunc-
tion is unclear, and if so, the underlying mechanisms are 
unknown. Addressing these issues is of clinical impor-
tance for avoiding deterioration of diastolic dysfunction 
in patients with severe diseases.
Glucose deprivation causes autophagy. Therefore, 
hyperglycemia is likely to inhibit autophagy [13]. Insuf-
ficient autophagy is thought to cause or promote heart 
failure [14–16]. However, a previous report showed that 
increased autophagy contributes to LV diastolic dysfunc-
tion in pulmonary arterial hypertension [17]. Glucose 
is the main source of energy in the failing heart. Per-
oxisome proliferator-activated receptor-γ coactivator 
(PGC)-1α, a transcriptional coactivator, is beneficial for 
heart failure by inducing a change in phenotype towards 
oxidative metabolism of energy [18]. The association 
between PGC-1α and autophagy in cardiomyocytes that 
are exposed to high glucose is unclear. However, several 
lines of evidence in non-cardiomyocytes have shown 
that PGC-1α promotes autophagy [19, 20]. Based on all 
of these findings, we hypothesize that acute hyperglyce-
mic stress suppresses diastolic function in preexistent 
heart disease by downregulating PGC-1α and inhibiting 
autophagic flux.
In the present study, we investigated the effect of acute 
hyperglycemia on LV diastolic function in a pressure-
overload model with preexistent diastolic dysfunction 
and insulin resistance. We also investigated the potential 
mechanisms related to PGC-1α and autophagic flux in 
cultured cardiomyocytes. Although echocardiographic 
evaluation of LV diastolic dysfunction is a routine proce-
dure in clinical practice, its accuracy is inferior to cardiac 
catheterization. Therefore, we used invasive LV hemody-




C57BL/6 male mice (9–10 weeks old) were subjected to 
TAC or sham operation as previously described [2, 21]. 
Briefly, prior to surgery, mice were anesthetized with 
a combination of ketamine (100  mg/kg) and xylazine 
(5 mg/kg) via intraperitoneal injection (ip), after intuba-
tion and artificial respiration, the chest-open was then 
opened via the second intercostal space to access the 
aorta. A non-absorbable 7–0 silk suture was tied around 
the aorta between the right innominate and left carotid 
arteries. This caused a constriction of approximately 
65 % using a 27 gauge-needle as a guide. For sham opera-
tions to serve as controls, mice received the same surgi-
cal procedure, except that the suture around the aorta 
was removed prior to closing the chest cavity. At various 
time points (1, 2 and 4 weeks) mice were sacrificed with 
an overdose of pentobarbital (150 mg/kg). The hearts and 
lungs were dissected to measure organ weight and to per-
form histological analysis.
Type 1 DM model
Ten-week-old male C57BL/6 mice were purchased and 
injected intraperitoneally with streptozocin (STZ) (Sigma 
Chemicals, St. Louis, USA) 70  mg/kg/day for 5  days. 
STZ was dissolved in 10  mmol/L sodium citrate buffer 
(pH 4.5). Control mice were injected with the buffer 
alone. Three days later, mice with a random blood glu-
cose level  >20  mmol/L were assigned to the hypergly-
cemic groups, whereas citrate buffer-treated mice were 
assigned to the control group. Six weeks later, mice were 
sacrificed with an overdose of pentobarbital (150 mg/kg), 
and the hearts were harvested for histological and molec-
ular examinations.
Invasive LV hemodynamic measurements
Thirty minutes or 2 weeks after surgery, mice were anes-
thetized, intubated, and ventilated as mentioned above. A 
1.4F Millar catheter (Millar Instruments, Inc., Houston, 
TX) was then inserted into the right carotid artery and 
advanced into the LV cavity. LV systolic pressure (LVSP) 
and LV end-diastolic pressure (LVEDP), maximum and 
minimum rates of change in LV pressure (dp/dt max and 
dp/dt min, respectively) were recorded. The exponential 
time constant of LV relaxation (τ) was calculated using 
Power Lab software (blood pressure module; AD Instru-
ments, Shanghai Trading Co, Shanghai, China). Some 
mice were treated with high glucose or mannitol (2  g/
kg ip) and the time-course of LV hemodynamics was 
recorded. For mice that received a high glucose load test, 
overnight fasting was performed before the test to avoid 
xylazine/ketamine anesthesia-induced hyperglycemia 
[22].
Blood glucose measurements
Plasma glucose (fasting or in response to high glucose or 
insulin treatment) measurements were performed in all 
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mice using a standard glucometer (Accu-Chek, Roche, 
Mannheim, Germany). Whole blood samples (3 μl) were 
taken from mouse tails with a glucose sensor inserted in 
the glucometer. Plasma glucose concentrations were read 
30 s later. Serum insulin levels were measured according 
to the protocol provided by the manufacturer (EIA-3440 
enzyme linked immunosorbent assay kit; Diagnosis-
related Group, Germany). Homeostasis model assess-
ment for insulin resistance (HOMA-IR) values were 
determined from results of the fasting blood glucose 
(FBG) and fasting insulin (FINS) tests, using the equa-
tion HOMA-IR  =  [FBG (mg/dl, 1  mmol/L  =  18  mg/
dL) × FINS (ng/ml)]/22.5.
Histology examination
The extent of myocardial fibrosis was measured, as 
described elsewhere [21, 23]. Hearts were fixed with 10 % 
formalin, and each heart was cut into four sections and 
stained with Masson trichrome.
Cell culture
Ventricular myocytes were prepared from Sprague–Daw-
ley rats (age, 1–2  days), which were obtained from the 
Animal Center of Southern Medical University. In brief, 
the rats were sacrificed by 2 % isoflurane inhalation. The 
hearts were quickly excised and immediately embed-
ded in freezing Hank’s solution. Cardiomyocytes were 
dispersed by digestion with 0.1  % trypsin and 0.03  % 
collagenase at 37  °C. The cells were then collected after 
differential adhesion of non-cardiomyocytes and plated 
at a density of 150–200 cells/mm2. Cardiomyocytes 
were incubated for 48  h in Dulbecco’s modified Eagle’s 
medium supplemented with 10  % fetal calf serum and 
then grown for 24 h under serum free conditions. Cells 
were treated with angiotensin II (1 μmol/L) and/or high-
glucose solution (25/50 mmol/L), and collected for pro-
tein extraction at 24 h.
Western blotting
Protein was obtained from cultured cardiomyocytes 
or hearts from STZ-treated mice, and was extracted 
in radio-immunoprecipitation assay lysis buffer. Sam-
ples were loaded onto 10  % sodium dodecyl sulfate–
polyacrylamide gels and the protein was transferred to 
polyvinyl difluoride membranes. Immunoblotting was 
then performed by using PGC-1α antibody (ab191838; 
Abcam, Shanghai, China) or autophagy antibodies 
(light chain 3 beta [LC3B]-I/II, 2775s; and P62, 5114s; 
Cell Signaling Technology, Danvers, MA), and GAPDH 
antibody (ARG10112; Arigo, Taiwan, China). Immuno-
reactive bands were visualized by the enhanced chemi-
luminescence method (Amersham, Piscataway, NJ) with 
a western blotting detection system (Kodak Digital Sci-
ence, Rochester, NY). These bands were quantified by 
densitometry with Scion Image software (Image J 1.42q; 
NIH, Bethesda, MD). We used the LC3B-II/loading con-
trol ratio rather than the LC3B II/LC3B-I ratio for quali-
fication of LC3-II expression levels according to a newly 
published guideline [24].
Assay of autophagic flux
To measure autophagic flux, cardiomyocytes were treated 
with bafilomycin A1 (Selleck; Texas, USA), a lysosomal 
inhibitor, at 100 nmol/L for 24 h. Cellular autophagic flux 
was estimated by western blots of LC3B-II and P62 pro-
tein as well as by tandem fluorescent mRFP-GFP-LC3. 
Cultured cardiomyocytes were infected with lentivirus 
carrying mRFP-GFP-LC3 (Cat. No. GPL2001; Gene-
chem Co., Shanghai, China) for 72  h (multiple of infec-
tion  =  25). subsequently, cells were either treated with 
angiotensin II (1  μmol/L), glucose (5.5 or 25  μmol/L), 
or bafilomycin A1 (100  nmol/L) for 24  h. Cells were 
then washed with PBS, fixed with 4 % paraformaldehyde 
and viewed under confocal laser scanning microscopy 
(Olympus FV1000; Japan). In merged images, puncta in 
autophagosome appeared yellow, while puncta in autol-
ysosomes appeared red.
Statistical analysis
All data analyses were performed using SPSS 17.0 soft-
ware (SPSS, Inc., Chicago, IL). Data are presented as 
mean ±  standard error of the mean. Comparisons were 
made using unpaired Student’s t tests and one-way or 
two-way ANOVA, as appropriate. P-values less than 0.05 
were considered statistically significant.
Results
Diastolic dysfunction appears in the early phase 
of pressure overload
In mice with TAC for 30 min, invasive evaluation of LV 
hemodynamics using a Millar catheter. In compari-
son with sham group, LVEDP and the exponential time 
constant of LV relaxation (τ) were greater, while LV dp/
dt  min was smaller in TAC group. These findings indi-
cated damage of diastolic function (Fig. 1a–h).
Diastolic dysfunction and insulin resistance appear in mice 
with cardiac hypertrophy
In mice with TAC for 2 weeks, the diastolic parameters 
LVEDP and τ were greater, dp/dt min and dp/dt max cor-
rected by LV systolic pressure was significantly smaller 
than in the sham group. These findings indicated that 
chronic TAC can induce diastolic and systolic dysfunc-
tion (Fig.  2a–e). Cardiac hypertrophy was identified 
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according to a significant greater heart to body weight 
ratio than in the sham group (Fig. 2f ). The results of an 
intraperitoneal glucose tolerance test showed signifi-
cantly higher peak glucose levels in the TAC group than 
in the sham group (Fig.  3a). This finding suggested glu-
cose tolerance in mice with cardiac hypertrophy. An 
insulin resistance test showed that plasma glucose con-
centrations at 30 min after insulin injection were higher 
in the TAC group than in the sham group (Fig. 3b). Addi-
tionally, the insulin resistance index HOMA-IR was sig-
nificantly correlated with the heart to body weight ratio 
(r = 0.5383, P < 0.01, Fig. 3c).
Acute hyperglycemic stress suppresses diastolic function 
in mice with preexistent diastolic dysfunction
In mice with TAC for 2 weeks and sham-operated mice, 
the time course of LV hemodynamics in response to 
acute hyperglycemia (glucose 2  g/kg, ip) was evaluated 
(Fig.  4a–e). We found that corrected LV dp/dt min was 
significantly decreased at 30 and 40  min after glucose 
overload in TAC mice, but not in sham mice (Fig.  4e). 
There was no significant change in corrected dp/dt max 
in the TAC and sham groups (Fig. 4d). Injection of manni-
tol with the same osmolarity as high glucose in TAC mice 
had no significant effect on LV hemodynamics (Fig. 4a–e). 
Autophagic marker proteins were also examined. LC3B-II 
was lower and P62 was higher in the TAC group than in 
the sham group. A high glucose load further suppressed 
LC3B-II and increased P62 in TAC mice (Fig. 4f ).
High glucose levels downregulate PGC‑1α and inhibit 
autophagic flux
We then investigated potential mechanisms related to 
autophagy in cultured neonatal rat cardiomyocytes. 
In cardiomyocytes, high glucose levels (≥25  mmol/L) 
enhanced angiotensin II-stimulated cell growth (Fig. 5a), 
significantly downregulated PGC-1α and LC3B-II, and 
upregulated the ubiquitin-binding autophagy recep-
tor P62 (Fig.  5b–f). An autophagic flux assay showed 
that bafilomycin A1 increased LC3B-II and P62 protein 
levels in the presence of angiotensin II and high glucose 
levels (Fig. 6a, b). A tandem fluorescent mRFP-GFP-LC3 
assay showed that angiotensin II and high glucose levels 
increased the ratio of autophagosomes to autolysosomes, 
which was enhanced by cotreatment with bafilomycin 
A1 (Fig. 6c, d). These results suggested that high glucose 
levels damaged mitochondrial energy metabolism and 
inhibited autophagic flux in the presence of the prohy-
pertrophic factor angiotensin II.
Chronic hyperglycemia induces LV diastolic dysfunction 
and inhibits autophagic flux
In mice with STZ-induced chronic hyperglycemia, 
plasma glucose levels, myocardial fibrosis, diastolic func-
tion and autophagic flux were evaluated 6  weeks later. 
In STZ-treated mice, mean blood glucose levels reached 
as high as 23 mmol/L (Fig. 7a). Additionally, myocardial 
fibrosis appeared in the heart (Fig. 7b), and LV diastolic 
dysfunction was detected as shown by an increase in 
LVEDP and τ as well as a decrease in dp/dt min (Fig. 7c–
f). Similar to the findings in high glucose-treated cardio-
myocytes, we found that PGC-1α was downregulated, 



























































































































Fig. 1 Diastolic dysfunction appears in the early phase of pressure 
overload. After 30 min of transverse aortic constriction (TAC) in C57 
mice, invasive hemodynamics were evaluated. a Left ventricular sys-
tolic pressure (LVSP). b Left ventricular end-diastolic pressure (LVEDP). 
c Heart rate. d Maximum rate of change in left ventricular pressure 
(dp/dt max). e Minimum rate of change in left ventricular pressure 
(dp/dt min). f Exponential time constant of relaxation (τ). g dp/dt 
max corrected with LVSP. h dp/dt min corrected with LVSP. *P < 0.05 
versus the sham group, n = 6 and 9 in the sham and TAC groups, 
respectively
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Fig. 2 Diastolic dysfunction and insulin resistance appear in mice with cardiac hypertrophy. After 2 weeks of TAC in C57 mice, invasive hemody-
namics were evaluated. a Representative recordings of left ventricular pressure and the rate of change in pressure. b Left ventricular systolic pres-
sure (LVSP). c Left ventricular end-diastolic pressure (LVEDP). d Maximum rate of change in left ventricular pressure (dp/dt max) corrected by LVSP. e 
Minimum rate of change in left ventricular pressure (dp/dt min) corrected by LVSP. f Heart to body weight ratio (HW/BW) and lung to body weight 
ratio (LW/BW). *P < 0.05 versus the sham group, n = 9 in each group
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Discussion
LV diastolic dysfunction can be induced in patients with 
hypertension, myocardial hypertrophy, or DM. These dis-
orders may also co-exist in patients with metabolism syn-
drome, which is likely to accelerate diastolic dysfunction. 
Our previous studies demonstrated that better glucose 
control with voglibose, an alpha-glycosidase inhibitor, or 
vildagliptin, a dipeptidyl-peptidase IV inhibitor, improves 
heart failure in mice with TAC [3, 25]. In patients with 
acute myocardial infarction, acute hyperglycemic stress 
at admission predicts poor long-term prognosis [12, 26], 
but the mechanisms are not clearly understood. Dias-
tolic dysfunction is a critical prognostic factor for car-
diovascular and some non-cardiovascular diseases [5, 9]. 
However, the effect of acute hyperglycemia on the hyper-
trophied heart with preexistent diastolic dysfunction and 
the mechanisms involved remain unclear. In this study, 
we found that acute hyperglycemia suppressed diastolic 
function in the hypertrophied heart, downregulated 
PGC-1α, a master regulator of mitochondrial biogenesis 
and function, and inhibited autophagic flux (see a sum-
mary in Fig. 8).
Acute hyperglycemia is a transient hyperglycemia 
referred to as stress-induced hyperglycemia. Acute 
hyperglycemia is commonly observed on admission and 
during hospitalization for cardiovascular diseases, and 
non-cardiovascular diseases, such as traumatic injury, 
burns and surgical intervention. This condition is asso-
ciated with an increase in morbidity and mortality com-
pared with hospitalized patients with normal glucose 
levels [27]. A recent report by Baranyai et al. [28] demon-
strated that cardioprotection exerted by remote ischemic 
preconditioning can be abolished by acute hyperglyce-
mia. Mebazaa et  al. [29] reported that hyperglycemia 
is a prognostic predictor for mortality of patients with 
acute heart failure. They found a 9 % increase in the risk 
of 30-day mortality for every 1 mmol/L increase in blood 
glucose concentration in patients with acute heart failure.
With regard to the effect of chronic hyperglycemia on 
the heart, Rubin et al. [30] reported that chronic hyper-
glycemia contributes to subclinical myocardial damage in 
persons without clinically evident coronary heart disease. 
This clinical finding is in agreement with our results that 
STZ-induced chronic hyperglycemia suppressed LV dias-
tolic function in mice without preexistent cardiovascular 
disease.
Pre-clinical diastolic dysfunction is prevalent and will 
progress to symptomatic heart failure [31]. In patients 
with DM or hypertension, diastolic dysfunction is a risk of 
progression to heart failure and death [32, 33]. In agree-
ment with previous studies [3, 34], in our study, we found 
that fasting glucose and glucose tolerance were impaired 
in hypertensive mice induced by TAC. This situation may 
be one of the reasons for diastolic dysfunction. Catena 
et al. [35] reported that impaired fasting glucose and glu-
cose tolerance were associated with more prominent dias-
tolic impairment in uncomplicated hypertensive patients, 
which is in consist with findings in our study.
Mitochondrial dysfunction of cardiomyocytes has been 








































































Fig. 3 Insulin resistance appears in mice with TAC for 2 weeks. a 
Plasma glucose concentrations in response to an intraperitoneal 
glucose tolerance test (IGTT, after fasting for 14 h, glucose 2 g/kg, 
ip). The insert shows fasting glucose levels. b Time course of plasma 
glucose concentrations after insulin injection. c Linear correlation 
between HOMA-IR and heart weight to body weight ratio (HW/BW) 
in the TAC and sham mice groups. *P < 0.05 versus the corresponding 
sham group, n = 16 and 12 in the sham and TAC groups, respectively, 
(panels a, b); n = 24 for panel c
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Fig. 4 Acute hyperglycemic stress suppresses diastolic function in mice with TAC for 2 weeks. a Representative time course recordings of left 
ventricular pressure (LVP) and the rate of rise and fall rate of LV (dp/dt). b Time course of left ventricular systolic pressure (LVSP). c Time course of 
left ventricular end-diastolic pressure (LVEDP). d Time course of corrected dp/dt max in response to glucose overload (2 g/kg, ip). e Time course of 
corrected dp/dt min in response to glucose overload. *P < 0.05 vs. the corresponding time point in the sham group, n = 5 per group. f Western blot 
analysis of LC3B-II and P62. *P < 0.05 vs. sham group; #P < 0.05 vs. TAC group, n = 5 per group
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Fig. 5 High glucose levels downregulate PGC-1α and inhibit autophagic flux. a Representative pictures of cultured neonatal rat cardiomyocytes 
(NRCs) stained with β-actin plus DAPI staining of the nucleus in response to angiotensin II stimulation with/without high glucose stimulation. 
Western blot analysis of PGC-1α (b, c), LC3B-II (d, e), and P62 (d, f) expression in cultured NRCs. *P < 0.05 vs. control group, #P < 0.05 vs. angiotensin II 
group. Each experiment was repeated four times
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Fig. 6 High glucose levels inhibit autophagic flux in cultured neonatal rat cardiomyocytes. a Western blot images of LC3B-II and P62 in cultured 
neonatal rat cardiomyocytes (NRCs) in the presence of bafilomycin A1. b Semi-quantitation of LC3B-II and P62 expression levels. c Representative 
immunofluorescent NRCs expressing mRFP-GFP-LC3. d Semi-quantitation of autophagosomes (yellow) and autolysosomes (red). *P < 0.05 vs. the 
autophagosomes in the corresponding group without bafilomycin A1 treatment; #P < 0.05 vs. the autolysosomes in the corresponding group 
without bafilomycin A1 treatment. Experiments were repeated four times. G5.5, glucose 5.5 mmol/L; G25, glucose 25 mmol/L; Ang II, angiotensin II; 
Baf, bafilomycin A1







































































































































Fig. 7 Chronic hyperglycemia levels induce LV diastolic dysfunction and inhibit autophagic flux in mice at 6 weeks after induction of type 1 DM. a 
Plasma glucose concentrations. b Representative images of H&E (top) and Masson stained (bottom) myocardial tissue. Scale bar = 10 µm. c Left ven-
tricular end-diastolic pressure (LVEDP). d Maximum of change in left ventricular pressure (dp/dt max). e Minimum rate of change in left ventricular 
pressure (dp/dt min). f Exponential time constant of relaxation (τ). g, h Western blot analysis of PGC-1α, LC3B-II, and P62 expression in myocardial 
tissues. *P < 0.05 vs. the sham group, n = 5 per group
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is a master regulator of mitochondrial biogenesis and 
breathing, and downregulation or loss of PGC-1α is 
detrimental for heart failure [36, 37]. Hyperglycemia-
induced reactive oxygen species in mitochondria play a 
critical role in the development of complications from 
diabetes. Overexpression of PGC-1α completely blocks 
hyperglycemia-induced production of mitochondrial 
reactive oxygen species and promotion of mitochon-
drial biogenesis [38]. Based on these lines of evidence, 
our study suggests high glucose-downregulated PGC-1α 
contributes to diastolic dysfunction. Recent studies have 
shown that stimulating mitochondrial function or con-
trol of glucose with voglibose or sitagliptin improves 
diastolic dysfunction [39, 40].
Diastolic dysfunction exists in the hypertrophied 
heart. Autophagy is diminished in response to pressure 
overload or β-adrenergic stimulation, although protein 
turnover is increased during hypertrophy [41, 42]. Wang 
et  al. [43] reported that low concentrations of angio-
tensin II induce autophagy while high concentrations 
diminish autophagy in cultured cardiomyocytes, which 
is in agreement with our results. Appropriated levels of 
autophagic flux are thought to maintain cellular homeo-
stasis and cell survival, which are beneficial for heart 
failure [44, 45]. Numerous studies have demonstrated 
that autophagy is impaired in the heart under DM [45], 
which is also in agreement with our findings. Zhang et al. 
[46] recently reported that an increase in autophagy pre-
vents cardiac fibrosis and inflammation in type 1 DM 
mice. Another study showed that caloric restriction 
improves diastolic dysfunction in diabetic rat hearts by 
enhancing autophagy [47]. In our study, we observed 
that acute stimulation with high glucose levels rapidly 
downregulated LC3B-II and upregulated P62. This find-
ing suggested inhibition of an autophagy by reducing 
formation of autophagosomes. Zhang et al. [48] reported 
that induction of autophagosome can be as fast as 15 min 
after treatment of retinal pigment epithelial cells with the 
drug N-retinyl-N-retinylidene ethanolamine.
In contrast to acute hyperglycemia, chronic hypergly-
cemia increased myocardial LC3B-II level. This situation 
could be due to long-term inhibition of autophagic flux 
as shown by upregulation of P62. Kanamori et  al. [49] 
reported diastolic impairment and in increase of LC3 II 
and P62 in mice with type 1 DM, which is consistent with 
our findings. However, the differences between acute and 
chronic hyperglycemia on autophagic activity need to be 
further clarified. Taken together, our findings suggest that 
reactivation of autophagy is likely to improve diastolic 
dysfunction induced by myocardial hypertrophy and DM.
Conclusion
Acute hyperglycemia suppresses diastolic function, 
damages mitochondrial energy signaling, and inhibits 
autophagic flux in prohypertrophic factor-stimulated 
cardiomyocytes. Our findings suggest that preventing 
acute hyperglycemia is of clinical importance for avoid-
ing deterioration of diastolic dysfunction in patients with 
LV hypertrophy. Modulation of autophagy may be a novel 
strategy for improving diastolic dysfunction induced by 
myocardial hypertrophy and DM.
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Fig. 8 Proposed hyperglycemia-mediated diastolic dysfunction 
signaling pathway. The solid and dotted arrows indicate evidence from 
our study and that from previous literature, respectively. ROS reactive 
oxygen species; uparrow activation and;  inhibition
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